Search - tctmd.com

Displaying 81 - 100 of 107

Sort: Relevancy | Date

News Industry News

Case Report: Use of OrbusNeich’s Genous™ Stent with Bivalirudin for Acute Coronary Syndrome Patients at Risk for Bleeding Due to Hematological Cancer

December 16, 2012

News Industry News

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

October 24, 2012

News Industry News

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

October 22, 2012

News Industry News

Revascularization with OrbusNeich’s Genous™ Stent May Enable the Safe and Early Discontinuation of Dual Antiplatelet Therapy for Patients with Increased Bleeding Risk

October 12, 2012

News Industry News

Health-Economic Analysis Suggests Medtronic Symplicity™ Renal Denervation System Is Cost-Effective and May Reduce Cardiovascular Event Risks for Patients with Treatment-Resistant Hypertension

September 12, 2012

News Industry News

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

August 20, 2012

News Industry News

Celladon Corporation Receives Patent from United States Patent and Trademark Office

July 19, 2012

News Industry News

OrbusNeich's Genous™ Stent Is Safe and Effective in Patients Who Discontinue Dual Antiplatelet Therapy (DAPT) Within 15 Days of Stent Placement

June 21, 2012

News Industry News

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

May 15, 2012

News Industry News

New Data From Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients

May 11, 2012

News Industry News

OrbusNeich’s Genous™ Stent Achieves Complete Endothelialization at Two Weeks

April 20, 2012

News Industry News

St. Jude Medical Initiates a Study to Evaluate the Economic Impact of FFR in Asia and Australia

February 14, 2012

News Industry News

TAVI at TCT: Enthusiasm Tempered by Poor Transapical Outcomes

November 09, 2011

News Industry News

Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT

November 08, 2011

News Industry News

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

November 08, 2011

News Industry News

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

November 08, 2011

News Industry News

Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery

November 08, 2011

News Industry News

Sunshine Heart Announces Results of Its C-Pulse(R) Feasibility Trial at the Transcatheter Cardiovascular Therapeutics Conference

November 06, 2011

News Industry News

Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011

November 04, 2011

News Industry News

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

November 04, 2011

Advertisement

Case Report: Use of OrbusNeich’s Genous™ Stent with Bivalirudin for Acute Coronary Syndrome Patients at Risk for Bleeding Due to Hematological Cancer

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

Revascularization with OrbusNeich’s Genous™ Stent May Enable the Safe and Early Discontinuation of Dual Antiplatelet Therapy for Patients with Increased Bleeding Risk

Health-Economic Analysis Suggests Medtronic Symplicity™ Renal Denervation System Is Cost-Effective and May Reduce Cardiovascular Event Risks for Patients with Treatment-Resistant Hypertension

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

Celladon Corporation Receives Patent from United States Patent and Trademark Office

OrbusNeich's Genous™ Stent Is Safe and Effective in Patients Who Discontinue Dual Antiplatelet Therapy (DAPT) Within 15 Days of Stent Placement

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

New Data From Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients

OrbusNeich’s Genous™ Stent Achieves Complete Endothelialization at Two Weeks

St. Jude Medical Initiates a Study to Evaluate the Economic Impact of FFR in Asia and Australia

TAVI at TCT: Enthusiasm Tempered by Poor Transapical Outcomes

Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery

Sunshine Heart Announces Results of Its C-Pulse(R) Feasibility Trial at the Transcatheter Cardiovascular Therapeutics Conference

Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content